Veru Inc. (VERU) is a publicly traded Healthcare sector company. As of May 21, 2026, VERU trades at $2.11 with a market cap of $34.03M and a P/E ratio of -1.38. VERU moved +2.84% today. Year to date, VERU is -5.24%; over the trailing twelve months it is -57.44%. Its 52-week range spans $2.05 to $14.20. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces VERU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Veru Schedules May 13 Financial Call, Eyes Phase 2b PLATEAU Interim Readout in Q1 2027: Veru will host its fiscal 2026 second-quarter financial call on May 13 at 8 a.m. ET, with a webcast and replay on its website. Its Phase 2b PLATEAU trial of enobosarm in 200 older obesity patients will report 36-week lean and fat mass interim data in Q1 2027 and topline results in Q4 2027.
| Metric | Value |
|---|---|
| Price | $2.11 |
| Market Cap | $34.03M |
| P/E Ratio | -1.38 |
| EPS | $-1.55 |
| Dividend Yield | 0.07% |
| 52-Week High | $14.20 |
| 52-Week Low | $2.05 |
| Volume | 83 |
| Avg Volume | 0 |
| Revenue (TTM) | $10.78M |
| Net Income | $-15.68M |
| Gross Margin | 0.00% |
1 analysts cover VERU: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.